|
|
 |
|
Viewing report
|
|
|
|
The North America Biotechnology Sectors : A Company and Industry Analysis (February 2005)
Mergent, Feb 2005, Pages: 32
This report looks at the biotechnology sectors in the United States and Canada, including the research, development and manufacturing and marketing and distribution segments
Current Environment - Key Points
- In 2004 the US biotech industry saw a greater number of profitable biotech firms with promising drugs in pipelines
- In the third quarter of 2004, most leading biotech firms in the US reported encouraging financial results
Sales growth continued to be driven primarily by core business segments and key products
- Acquisitions in the US biotech-pharmaceuticals industry during the first half of 2004 nearly doubled to 315 from 177 in the second half of 2003
- The Canadian biotech sector moved towards fuller maturity, following a rebound in 2003
Firms accelerated product manufacture; some more than doubled their investments in research and development
- The majority of leading Canadian biotechs displayed continued growth in financial performance, mainly driven by positive market demand for companies- key leading products
Industry Profile - Key Points
- The US remains the global biotech front-runner in terms of revenue generation, with a sector worth more than US$35 billion a year
- The US accounts for nearly two thirds of all biotech crops grown globally and agricultural biotech remains a major area for US biotech companies
- The booming US biotech sector remains a major employer of the American workforce
By 2014, the industry is expected to be responsible for over 3,600,000 jobs in total
- Canada has more biotech companies per capita than any other country, and the industry ranks third globally behind the US and the UK in biotech revenues
- Sustained growth in the Canadian biotech industry is helping venture investment in the industry to pick up, albeit at a gradual pace
Market Trends and Outlook - Key Points
- The US is becoming a global leading force in the development of transgenic animals (animals with genes inserted from another organism), which is seen as an emerging solution to disease treatment, shortage of transplant organs and food production
- Second generation enzymes are being rapidly developed in the US, and are viewed as a new phase in industrial biotech
- With a rapidly growing scientific base, and an ever-growing number of profitable companies and promising product pipelines, the US biotech industry looks set for greater success in the coming year
- Canada is recognizing the potential of biology-based products (bioproducts) with the Government investing more R&D in this sector
- The Canadian Government is making commercialization of the biotech industry a top priority, as part of its goal to make Canada a world-leading nation in terms of R&D performance
Customers who bought this item also bought
Biotech 2009-Life Sciences: Navigating the Sea Change
Booming Biotech Market in India
Understanding the Global Biotech Industry
US Biotech Market Analysis
Biotech Life Sciences: A 20/20 Vision to 2020
Global Biotech Industry Monitor
The North America Biotechnology Sectors : A Company and Industry Analysis (August 2007)
China Biotech 2008
North America Biotechnology Sectors : A Company and Industry Analysis (February 2008)
The North America Biotechnology Sectors : A Company and Industry Analysis (February 2007)
The Biotech Industry at 30,000 Feet
Biotech M&A Strategies: Deal Assessments, Trends and Future Prospects
|
|
|
|
